Loading patent…
AssigneesUniversity of Massachusetts, The Texas A&M University System
InventorsManos GKIKAS, Phanourios TAMAMIS, Sai JONNALAGADDA
Estimating the term…
A complex includes an amyloid peptide complexed with a cholinesterase inhibitor, an NMDA receptor antagonist, or a combination, of a cholinesterase inhibitor and an NMDA receptor antagonist, wherein the amyloid peptide comprises X1X2GAIIGX3X4 (SEQ ID NO: 2), wherein X1 and X4 are each independently YF or FY, and X2 and X3 are each 1 amino acid long, and are each independently T, N, S, or Q; or X2 and X3 are each 2 amino acid long and X2 is (Y or F)T, (Y or F)N, (Y or F)S or (Y or F)Q, and X3 is T(Y or F), N(Y or F), S(Y or F) or Q(Y or F), wherein the amyloid peptide self-assembles into amyloid fibrils, and wherein the peptide has a total length of 11-13 amino acids.
) A complex comprising an amyloid complexed with a cholinesterase inhibitor, an NMDA receptor antagonist, or a combination;
) The complex of claim 1, wherein the amyloid peptide comprises FYTGAIIGNYF (SEQ ID NO:
) The complex of claim 1, wherein the cholinesterase inhibitor comprises donepezil, galantamine, rivastigmine, tacrine, neostigmine, or edrophonium.
) The complex of claim 1, wherein the NMDA receptor antagonist comprises memantine, amantadine, ketamine, dizoclopine, or d-cycloserine.
) A pharmaceutical composition comprising the complex of claim 1 and a pharmaceutically acceptable excipient.
) The pharmaceutical composition of claim 5, in the form of a composition for oral administration, topical application, or intranasal administration.
) A method of treating a neurodegenerative disease, comprising administering to a subject in need thereof the complex of claim 1.
) The method of claim 7, wherein the neurodegenerative disease is Alzheimer's disease, Parkinsons' disease, Myasthenia gravis, or Amyotrohic lateral sclerosis.
) The method of claim 7, wherein the neurodegenerative disease is Alzheimer's disease.